

Express Mail Label No. EV 901256191 US Dated: January 5, 2007

Docket No.: 2001377.123-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregor CEVC Confirmation No.: 2670
Application No.: 09/284,683 Art Unit: 1615
Filed: June 24, 1999 Examiner: G. S. Kishore
Title: PREPARATION FOR THE TRANSPORT OF AN ACTIVE
SUBSTANCE ACROSS BARRIERS

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, the Examiner's attention is invited to the attached Form PTO/SB/08, listing references AA-AZ, AA1-AV1, BA-BR, and CA-CJ. A copy of references BA-BR and CA-CJ is attached. The undersigned respectfully requests that the Examiner consider these references, make them record by initialing the enclosed Form PTO/SB/08, and forward a copy of the Examiner-initialed Form with the next communication.

A fee of \$180.00 is believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. The Commissioner is authorized to debit any necessary fee from, or credit any overpayment relating to the above-identified application to, Deposit Account No. 08-0219.


Dated: January 5, 2007

Respectfully submitted,

Matthew E. Langer
Reg. No. 36,343

Matthew E. Langer
Registration No.: 36,343

Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 10022
(212) 230-8800 (telephone)
(212) 230-8888 (facsimile)



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	09/284,683
				Filing Date	June 24, 1999
				First Named Inventor	Gregor CEVC
				Art Unit	1615
				Examiner Name	G. S. Kishore
Sheet	1	of	3	Attorney Docket Number	2001377.123-US1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	AA	US-4,666,747	05-19-1987	Quinn et al.	
	AB	US-4,731,210	03-15-1988	Weder et al.	
	AC	US-4,746,509	05-24-1988	Haggiage et al.	
	AD	US-4,783,450	11-08-1988	Fawzi et al.	
	AE	US-5,104,661	04-14-1992	Lau	
	AF	US-5,145,684	09-08-1992	Liversidge et al.	
	AG	US-5,154,930	10-13-1992	Popescu et al.	
	AH	US-5,498,418	03-12-1996	Beutner et al.	
	AI	US-5,510,118	04-23-1996	Bosch et al.	
	AJ	US-5,552,160	09-03-1996	Liversidge et al.	
	AK	US-5,648,095	07-15-1997	Illum et al.	
	AL	US-5,654,337	08-05-1997	Roentsch et al.	
	AM	US-5,716,638	02-10-1998	Touitou et al.	
	AN	US-5,763,422	06-09-1998	Lichtenberger et al.	
	AO	US-5,837,289	11-17-1998	Grasela et al.	
	AP	US-5,858,330	01-12-1999	Boltri et al.	
	AQ	US-5,874,422	02-23-1999	Krause et al.	
	AR	US-5,985,860	11-16-1999	Toppo	
	AS	US-6,028,066	02-22-2000	Unger	
	AT	US-6,045,827	04-04-2000	Russell	
	AU	US-6,069,172	05-30-2000	Bertini et al.	
	AV	US-6,083,996	07-04-2000	Buyuktimkin et al.	
	AW	US-6,193,996	02-27-2001	Effing et al.	
	AX	US-6,200,598	03-13-2001	Needham	
	AY	US-6,214,386	04-10-2001	Santus et al.	
	AZ	US-6,248,353	06-19-2001	Singh	
	AA1	US-20010012849-A1	08-09-2001	Wechter	
	AB1	US-6,294,192	09-25-2001	Patel et al.	
	AC1	US-6,303,141	10-16-2001	Fischer et al.	
	AD1	US-20020003179-A1	01-10-2002	Verhoff et al.	
	AE1	US-20020012680-A1	01-31-2002	Patel et al.	
	AF1	US-20020037877-A1	03-28-2002	Singh	
	AG1	US-20020048596-A1	04-25-2002	CEVC	
	AH1	US-6,387,383	05-14-2002	Dow et al.	
	AI1	US-20020106345-A1	08-08-2002	Uhrich et al.	
	AJ1	US-20020119188-A1	08-29-2002	Niemiec et al.	
	AK1	US-6,448,296-A1	09-10-2002	Yasueda et al.	
	AL1	US-6,451,339-A1	09-17-2002	Patel et al.	
	AM1	US-20020147238-A1	10-10-2002	Jerussi et al.	
	AN1	US-6,562,370-A1	05-13-2003	Luo et al.	
	AO1	US-6,582,724-A1	06-24-2003	Hsu et al.	
	AP1	US-6,586,000-A1	07-01-2003	Luo et al.	
	AQ1	US-6,645,520-A1	11-11-2003	Hsu et al.	
	AR1	US-6,645,529-A1	11-11-2003	Gergely et al.	
	AS1	US-6,726,598	04-27-2004	Jarvis et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

6005885



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	09/284,683
				Filing Date	June 24, 1999
				First Named Inventor	Gregor CEVC
				Art Unit	1615
				Examiner Name	G. S. Kishore
Sheet	2	of	3	Attorney Docket Number	2001377.123-US1

AT1	US-6,835,392-A1	12-28-2004	Hsu et al.	
AU1	US-20030099694	5-29-2003	Cevc et al.	
AV1	US-20050123897	6-9-2005	Cevc et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	BA	English Language Abstract of WO-92/22292	12-23-1992	SCHWARZ PHARMA AG		√
	BB	EP-0 355 095	08-04-1993	THE LIPOSOME COMPANY, INC.		
	BC	English Language Abstract of WO-94/26257	11-24-1994	LTS LOHMANN THERAPIE-SYSTEME GMBH & CO.		√
	BD	English Language Abstract of WO-96/29999	10-03-1996	HEXAL AG		√
	BE	EP-0 382 716	01-28-1998	WARNER-LAMBERT CO.		
	BF	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		
	BG	WO-98/30215	07-16-1998	CILAG AG		
	BH	WO-99/22703	05-14-1999	LURIDENT LTD.		
	BI	WO-00/00597	01-06-2000	THE UNIVERSITY OF MANITOBA		
	BJ	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
	BK	EP-0 995 435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.		
	BL	WO-00/25822	05-11-2000	John C. Grasela, et al.		
	BM	WO-00/44350	08-03-2000	IDEA AG		
	BN	WO-00/50007	08-31-2000	LIPOCINE, INC.		
	BO	WO-01/12155	02-22-2001	LIPOCINE, INC.		
	BP	WO-02/07767	01-31-2002	ALCON UNIVERSAL, LTD.		
	BQ	WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES		
	BR	EP-1 031 346	05-02-2002			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Calpena, A. et al., "Influence of the Formulation on the In Vitro Transdermal Penetration of Sodium Diclofenac," <i>Arzneim.-Forsch./Drug-Res</i> , 49(II), 1012-1017 (1999).	
	CB	Carafa, M. et al. "Lidocaine-loaded Non-ionic Surfactant Vesicles: Characterization and In Vitro Permeation Studies," <i>International Journal of Pharmaceutics</i> 231:21-32. (2002).	
	CC	Cevc, G. "Drug Delivery Across the Skin," <i>Exp. Opin. Invest. Drugs</i> (1997) 6(12) 1887-1937.	
	CD	Cevc, G. et al. "Newly, Highly Efficient Formulation of Diclofenac for the Topical, Transdermal Administration in Ultradeformable Drug Carriers, Transfersomes," <i>Biochimica et Biophysica Acta</i> 1514 (2001) 191-205.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

6005885



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/284,683
				Filing Date	June 24, 1999
				First Named Inventor	Gregor CEVC
				Art Unit	1615
				Examiner Name	G. S. Kishore
				Attorney Docket Number	2001377.123-US1
Sheet	3	of	3		

CE	Cevc, G. et al., "Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo," Journal of Controlled Release 45 (1997) 211-226.	
CF	Friedrich, I. et al., "Physicochemical Characterization of a Reverse Micellar Solution after Loading with Different Drugs," Pharmazie 55 (2000) 10, 755-758.	
CG	Gesztes, A. et al., "Topical Anesthesia of the Skin by Liposome-Encapsulated Tetracaine, Anesth Analg 1988 67 1079-1081.	
CH	Schramlova, J. et al., "The Effect of an Antiphlogistic Incorporated in Liposomes on Experimentally Induced Inflammation," Folia Biologica (Praha) 43, 195-199 (1997).	
CI	Stoye, I. et al., "Transformation of a Liposomal Dispersion Containing Ibuprofen Lysinate and Phospholipids into Mixed Micelles - Physico-chemical Characterization and Influence on Drug Permeation through Excised Human Stratum Corneum, European Journal of Pharmaceuticals and Biopharmaceuticals 46 (1998) 191-200.	
CJ	Valenta, C. et al., "Evaluation of Novel Soya-lecithin Formulations for Dermal use containing Ketoprofen as a Model Drug," Journal of Controlled Release 63 (2000) 165-173.	

²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

6005885